Aehr Test Systems [NASDAQ:AEHR] provides advanced test and burn-in systems for the semiconductor industry. These specialized systems are critical for ensuring the long-term reliability of semiconductor chips, especially those used in demanding applications like artificial intelligence (AI) and high-performance data centers. The company's innovative technology helps identify and screen out potentially faulty semiconductors, enhancing overall chip reliability before they are integrated into final products.
On April 8, 2026, a leading analyst from Craig-Hallum set a price target of $68 for AEHR stock. At the time, the stock's price was $63.16, representing a potential upside of 7.66%. As highlighted by TheFly, the firm issued an AEHR stock upgrade, citing what it sees as improving business momentum and positive outlook for the semiconductor testing market.
This positive outlook follows a significant 25.7% surge in AEHR's stock after its recent fiscal third-quarter results. While sales of $10.3 million were slightly below analyst expectations, the company reported a smaller-than-expected adjusted loss of $0.05 per share. This impressive performance beats estimates by $0.02 per share, signaling strong operational control and efficient management within the semiconductor equipment sector.
The positive momentum is further supported by a remarkable six-fold increase in new orders, known as bookings, which reached $37.2 million. This led to an impressive book-to-bill ratio of over 3.5x. A book-to-bill ratio above one indicates that the company is securing new orders faster than it is shipping current ones, strongly suggesting robust future revenue growth and sustained demand for Aehr Test Systems' solutions.
Looking ahead, AEHR's backlog, representing secured future revenue, stands at a healthy $38.7 million. The company anticipates bookings for the second half of fiscal 2026 to reach the high end of its $60 million to $80 million forecast. This optimistic outlook is primarily driven by expected orders from a major customer for its advanced AI processors, underscoring AEHR's pivotal role in the expanding AI chip testing market.
